Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two cases of successful immunomodulation in Japanese kidney transplant recipients with cytokine release syndrome following coronavirus disease. Case presentation: Two patients who had been receiving long-term immunosuppressant therapy developed coronavirus disease-associated pneumonia caused by cytokine release syndrome, following immunosuppressant dosage reduction. However, they recovered immediately after administration of tocilizumab with or without dexamethasone. Conclusion: The immunosuppressant dosage should be reduced to restore host immunity; however, immunomodulation should be considered in cases of suspected cytokine release syndrome.

Cite

CITATION STYLE

APA

Takamoto, D., Sasaki, H., Kataoka, H., Kodama, F., Higuchi, H., Hirano, T., … Tanaka, H. (2022). Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease. IJU Case Reports, 5(5), 373–377. https://doi.org/10.1002/iju5.12492

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free